A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma (MODIFY)

The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 Weeks

The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).

Study Overview

• Status: Not yet recruiting
• Conditions: Asthma
• Intervention / Treatment: Drug: Placebo; Drug: Depemokimab

• Study Type: Interventional
• Enrollment (Estimated): 456
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: US GSK Clinical Trials Call Center; Phone Number: 877-379-3718; Email: GSKClinicalSupportHD@gsk.com
• Study Contact Backup: Name: EU GSK Clinical Trials Call Center; Phone Number: +44 (0) 20 89904466; Email: GSKClinicalSupportHD@gsk.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults and adolescents >=12 years of age, at the time of signing the informed consent/assent. For countries where local regulations or the regulatory status of study medication permit enrolment of adults only, participants recruited will be >=18 years of age.
• Participants must have a documented physician diagnosis of asthma for >=2 years that meets the National Heart, Lung, and Blood Institute, National Institute for Health and Care Excellence or Global Initiative for Asthma guidelines

• Have previously confirmed history of at least 2 exacerbations over the last 3 years prior to screening, with at least 1 of those exacerbations occurring in the previous year prior to Screening Visit 1.

  • Exacerbation requiring treatment with systemic Corticosteroid (CS), for at least 3 days, despite the use of low to medium dose Inhaled corticosteroids (ICS)/ Long-acting beta2-adrenergic receptor agonist (LABA).

• A well-documented requirement for treatment with low to medium dose ICS/LABA (in the 12 months prior to screening visit. Treatment should be stable for 3 months prior to screening. If participants are taking Maintenance and Reliever Therapy/Single Maintenance and Reliever Therapy regularly, the total daily dose should be incorporated into the assessment of low or medium dose ICS.

  • Study will limit enrolment to a maximum of 40 percent (%) of participants on low dose ICS/LABA.

• Sex and Contraceptive/Barrier Requirements Male or eligible female Participants:

  • Male Participants: Contraception for male participants with female partners is not required.
  • Female Participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
  • Is a participant of nonchildbearing potential (PONCBP) OR
  • Is a participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (<)1%, from at least 14 days prior to the first dose of study intervention until at least 35 weeks after the last administered dose of study intervention.
  • A POCBP must have a negative highly sensitive serum pregnancy test at Screening Visit 1, Exit Visit 11 or Withdrawn from study visit, and a negative highly sensitive urine pregnancy test within 24 hours before the first dose of study intervention.
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated in relationship to the first dose of study intervention).
  • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
• Capable of giving signed informed consent/assent as which includes compliance with the requirements Randomization inclusion criteria-

• Type 2 high disease at risk of asthma exacerbations as defined by either:

  • An elevated peripheral blood eosinophils (EOS) count of >=500 cells/milliliter (mL) at screening or >=500 cells/mL in the last 3 months prior to the screening visit.

OR

• An elevated peripheral blood EOS count of >=300 cells/mL at screening OR >=300 cells/mL in the last 3 months prior to the screening visit AND

  • Fractional exhaled nitric oxide >=35 parts per billion (ppb) at screening. OR
  • Documented current Chronic Rhinosinusitis with Nasal Polyps.

Exclusion Criteria:

• Participants have had 3 or more exacerbations in the last year prior to Visit 1.
• Participants on maintenance OCS or high dose ICS/LABA for asthma.
• Participants with a duration of asthma greater than (>)20 years.
• Presence of a known pre-existing, clinically important lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or a history of lung cancer. Participants with current diagnoses of emphysema or chronic bronchitis (Chronic Obstructive Pulmonary Disease other than asthma) are excluded.
• Participants with other conditions that could lead to elevated EOS such as hypereosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome) or eosinophilic esophagitis.
• Participants who developed an exacerbation within 4 weeks before screening.
• Participants with a known, pre-existing parasitic infestation within 6 months prior to screening unless treated and evidenced to have been resolved.
• A known immunodeficiency (e.g. human immunodeficiency virus), other than that explained by the use of CS taken as therapy for asthma.
• A current malignancy or previous history of cancer in remission for less than 12 months prior to screening.
• Participants who have known, pre-existing, clinically significant cardiac, endocrine, autoimmune, metabolic, neurological, psychiatric, renal, gastrointestinal, hepatic, hematologic or any other system abnormalities that are uncontrolled with standard treatment.
• Participants with current diagnosis of vasculitis.
• Participants who have received treatment with any approved or investigational biologic monoclonal antibody (mAb).
• A history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to the first dose of study intervention.
• Current smokers or former smokers with a smoking history of >=20 pack years (number of pack years = [number of cigarettes per day/20] * number of years smoked) and vapers.
• Participants with allergy/intolerance to a mAb or biologic or any of the excipients of depemokimab.
• Participants who are pregnant or breastfeeding.
• Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations.
• Evidence of clinically significant abnormality in the hematological, biochemical or urinalysis screen at screening (Visit 0), as judged by the investigator.

Liver safety exclusion criteria:

• Alanine aminotransferase (ALT) >2* Upper limit of normal (ULN).
• Total bilirubin >1.5*ULN; For participants with Gilbert's syndrome: can be included with total bilirubin >1.5*ULN as long as direct bilirubin is less than or equal to (<=)1.5*ULN.
• Cirrhosis or current unstable liver or biliary disease as per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.

Cardiac safety exclusion criteria:

• Electrocardiogram (ECG) Assessment: QTc corrected by Fridericia's formula (QTcF) >=450 millisecond (msec) or QTcF >=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from Screening Visit, or in the 12-lead ECG machine read at Visit 1.
• Participants are excluded if an abnormal ECG finding from central over read of the 12 lead ECG conducted at Screening Visit is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the investigator.

Randomization exclusion criteria:

• ECG Assessment: QTcF >=450 msec or QTcF >=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from Screening Visit, or in the 12 lead ECG machine read at Visit 1.
• ALT >2*ULN.
• Total bilirubin >1.5*ULN; For participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is <=1.5*ULN.
• Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable.
• Maintenance Asthma Therapy: Any changes in the dose or regimen of baseline ICS and/or additional controller medication (except for treatment of an exacerbation) during the run-in period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Depemokimab; Participants will be administered depemokimab along with standard of care (SoC).	Drug: Depemokimab; Depemokimab will be administered; Other Names: GSK3511294
Placebo Comparator: Placebo; Participants will be administered placebo along with SoC	Drug: Placebo; Placebo will be administered

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annualized rate of clinically significant exacerbations	A clinically significant exacerbation is defined as a worsening of asthma requiring the use of systemic corticosteroids.	Up to Week 156

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants with clinical remission at 2 years	Clinical remission defined as no clinically significant asthma exacerbations during the first 2 years of the treatment period, and no maintenance oral corticosteroids (OCS) for asthma at 2 years, and well controlled asthma based on an Asthma Control Test (ACT) greater than or equal to (>=) 20 at 2 years, and no deterioration of lung function.	At 2 years
Change from Baseline in Asthma Quality of Life Questionnaire (AQLQ) total overall score at 2 years	The AQLQ is a 32-item self-administered questionnaire designed to measure the impact of asthma on an individuals daily life over the last 2 weeks across four domains: Symptoms, Activity Limitations, Emotional Function, and Environmental Stimuli. Each item is scored on a 7 point scale (1 = severe impairment; 7 = no impairment). The overall score is the mean of all 32 items and ranges from 1.0 (worst quality of life) to 7.0 (best quality of life). Higher scores indicate better quality of life (QoL), with lower impairment on daily functioning and well-being.	Baseline and at 2 years
Change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score at 2 years	The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquire about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath, and wheeze) over the previous week. The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control.	Baseline and at 2 years
Change from Baseline in post-Bronchodilator Forced expiratory volume in 1 second (FEV1) at 2 years	FEV1 is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing.	Baseline and at 2 years
Change from Baseline in pre-Bronchodilator FEV1 at 2 years	FEV1 is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing.	Baseline and at 2 years

Collaborators and Investigators

• Sponsor: GlaxoSmithKline
• Investigators: Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (Estimated): March 6, 2026
• Primary Completion (Estimated): July 1, 2030
• Study Completion (Estimated): July 1, 2030

Study Registration Dates

• First Submitted: March 2, 2026
• First Submitted That Met QC Criteria: March 2, 2026
• First Posted (Actual): March 6, 2026

Study Record Updates

• Last Update Posted (Actual): March 6, 2026
• Last Update Submitted That Met QC Criteria: March 2, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Depemokimab; GSK3511294; MODIFY; Type 2 asthma
• Additional Relevant MeSH Terms: Immune System Diseases; Respiratory Tract Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Asthma
• Other Study ID Numbers: 222926; 2025-524463-20 (Registry Identifier: EU CT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://d3l8i7lo48obsd.cloudfront.net/gsk-patient-level-data-sharing-july2025-1-Bgwa1UthxvluYbWYTThw.pdf
• IPD Sharing Time Frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
• IPD Sharing Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No